<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293407</url>
  </required_header>
  <id_info>
    <org_study_id>19398</org_study_id>
    <nct_id>NCT03293407</nct_id>
  </id_info>
  <brief_title>Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension</brief_title>
  <acronym>VENTASTEP</acronym>
  <official_title>Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the observational VENTASTEP study is to investigate the potential use of
      device-based measures as outcome-surrogates for clinical assessments in PAH-patients using
      the new Breelib nebulizer in a real life setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Six-minute walking distance (6MWD)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Clinical outcome measured by study nurse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of laboratory results of the biomarkers NT-pro BNP/BNP</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Health related Quality of Life-EuroQol five dimensions questionnaire (EQ-5D)</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of World Health Organization functional class</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Distance Walked per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changed of Number of Steps per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of number of floors climbed (10 feet) per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of time spent at home per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of number of relevant location changes per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of number of times leaving home per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of number of times standing up per day</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of 6MWD</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Device based outcome measured by smart device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average daily inhalation duration per session</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average number of daily inhalations</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sleep quality</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measured by Pittsburgh Sleep Quality Index (PSQI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to 3 months after first inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of heart rate during 6MWD</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average daily proportion of complete/incomplete inhalations</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average association between physical activity level (wearable device based) and time to last inhalation</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rates during baseline and observation period</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>BAYQ6256_Ventavis</arm_group_label>
    <description>Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost (Ventavis, BAYQ6256)</intervention_name>
    <description>Using Breelib device</description>
    <arm_group_label>BAYQ6256_Ventavis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breelib nebulizer</intervention_name>
    <description>Used for inhalation of Ventavis</description>
    <arm_group_label>BAYQ6256_Ventavis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary hypertension at intermediate risk and WHO FC III who failed to
        respond adequately to initial therapy with one or more PAH drugs or who clinically
        deteriorated after initial treatment response and for whom a therapy escalation with
        Ventavis (Iloprost) has been agreed by patient and physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ventavis-treatment naïve patients aged ≥18 years at initiation of Ventavis (Iloprost)
             therapy diagnosed with pulmonary arterial hypertension WHO FC III

          -  Patients who are planned to be treated with Ventavis (Iloprost) and where the decision
             to use the Breelib has been agreed by physician and patient

          -  Patients who are willing to wear a smart watch (iWatch2) over the observation period
             of 3 months ± 2 weeks

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients allergic to Nickel and Methacrylates

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

